← Back to Search

Other

ABBV-444 Drops for Dry Eye Syndrome

Phase 3
Waitlist Available
Research Sponsored by AbbVie
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to day 30
Awards & highlights

Study Summary

This trial will test a new drug to treat Dry Eye Disease. 40 adult participants will receive ABBV-444 eye drops as needed for 30 days to evaluate symptoms & tolerability. They will have regular visits & assessments, & may experience higher treatment burden than usual.

Eligible Conditions
  • Dry Eye Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to day 30
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to day 30 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change from Baseline in Ocular Surface Disease Index (OSDI) Score
Secondary outcome measures
Change from Baseline in Patient Eye Drop Experiences (Visual Analog Scale)
Change from Baseline in Symptom Scores (Visual Analog Scale) within 5 Minutes Post Administration of ABBV-444

Trial Design

1Treatment groups
Experimental Treatment
Group I: ABBV-444Experimental Treatment1 Intervention
Participants will administer 1-2 drops of ABBV-444 in each eye as needed but minimally twice a day for 30 days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ABBV-444
2023
Completed Phase 3
~40

Find a Location

Who is running the clinical trial?

AbbVieLead Sponsor
971 Previous Clinical Trials
505,088 Total Patients Enrolled
ABBVIE INC.Study DirectorAbbVie
406 Previous Clinical Trials
148,977 Total Patients Enrolled

Media Library

ABBV-444 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05878067 — Phase 3
Dry Eye Syndrome Research Study Groups: ABBV-444
Dry Eye Syndrome Clinical Trial 2023: ABBV-444 Highlights & Side Effects. Trial Name: NCT05878067 — Phase 3
ABBV-444 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05878067 — Phase 3
~21 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top